IPCA Laboratories has been granted a patent for a novel key intermediate in the synthesis of rivaroxaban, a blood thinner. The invention includes a crystalline form of the intermediate and a method for preparing rivaroxaban. This innovation offers an improved and efficient process for producing the medication. GlobalData’s report on IPCA Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights IPCA Laboratories Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on IPCA Laboratories, Peptide pharmacophores was a key innovation area identified from patents. IPCA Laboratories's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Intermediate compound for synthesizing rivaroxaban

Source: United States Patent and Trademark Office (USPTO). Credit: IPCA Laboratories Ltd

A recently granted patent (Publication Number: US11891384B2) discloses a novel compound, 4-{4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate of Formula-5. This compound is claimed in the patent as having unique crystalline forms, with specific characteristics outlined in the claims.

One of the crystalline forms of the compound is characterized by a DSC peak at 206.84°C, as specified in claim 3. Additionally, claim 4 details another crystalline form with a distinct XRPD pattern, featuring 2? values at 10.26, 13.70, 19.67, 20.37, 23.08, and 24.76+/-0.2. These specific characteristics of the crystalline forms of 4-{4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate are essential aspects of the patented invention, providing valuable insights for potential applications and further research in the field.

To know more about GlobalData’s detailed insights on IPCA Laboratories, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies